Correct identification of incomplete Kawasaki disease

Tianhua Li¹, Jie Feng¹, Na Li¹ and Tingting Liu²

Abstract
Incomplete Kawasaki disease (IKD) is characterized by a longer fever time, younger age of onset, and higher incidence of coronary artery disease compared with complete Kawasaki disease. Kawasaki disease is often difficult to diagnose early because of its incomplete clinical symptoms. This issue could delay treatment and harm the health of the child. This article reviews the clinical characteristics and pathogenesis of IKD to help clinicians understand the symptoms of IKD, make the correct diagnosis, and provide timely treatment.

Keywords
Incomplete Kawasaki disease, coronary artery lesion, children, fever, young age, aneurysm, intravenous immunoglobulin

Date received: 10 February 2021; accepted: 18 February 2021

Introduction
Kawasaki disease (KD), also called mucocutaneous lymph node syndrome, was first reported by Tomisaku Kawasaki in Japan in 1967.¹ A diagnosis of classical KD, also called complete KD (CKD), is usually made when the patient has a fever lasting >5 days and four of the following five manifestations: (1) changes to the oral mucosa, such as lip fissures, erythema, or strawberry tongue; (2) changes to the extremities, including edema, redness, or desquamation; (3) polymorphous rash; (4) nonpurulent bilateral eye injection; and (5) nonpurulent cervical lymphadenopathy (>15 mm).² The etiology and pathogenesis of KD are incompletely understood. Rigante recently investigated the potential role of viruses in

¹Department of Paediatrics, Weifang People’s Hospital, Weifang City, Shandong Province, China
²Department of Ultrasound, Weifang People’s Hospital, Weifang City, Shandong Province, China

Corresponding author:
Tingting Liu, Department of Ultrasound, Weifang People’s Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang City, Shandong Province 261041, China.
Email: 308099700@qq.com
triggering the inflammation that generates KD in genetically predisposed children. Findings appeared to suggest that a dysregulated immune response to various microbial agents, such as viruses, may be the main cause of the onset of KD. To date, however, no definite link has been irrefutably found between a single infection and KD.

The incidence of incomplete KD (IKD) has steadily grown over the last several years. Indeed, the incidence rate of IKD reported in Japan is 15.0% to 36.2%, and reports from many hospitals in China indicate an incidence rate of >40%. A hospital in India reported an incidence rate of 48.4% for IKD, which is similar to the rates published by most countries. Unfortunately, the incidence rate of IKD is even higher for small neonates. Diagnosing KD in a timely manner is fairly challenging, which means clinical treatment is often delayed. This disease poses a significant economic burden to society and affected families. Therefore, understanding KD and conducting a comprehensive analysis of IKD are necessary to correctly diagnose KD.

KD is an acute small-arterial vasculitis syndrome that mainly involves the coronary arteries, leading to their dilation. In severe cases, KD can lead to coronary aneurysm, ischemic cardiomyopathy, and myocardial infarction; KD is a leading cause of acquired heart disease worldwide. Because the clinical symptoms of IKD are incomplete, difficulties in diagnosis, treatment delays, and increased complications are fairly common. Misdiagnosis or missed diagnosis of KD may lead to further development of this disease and an increased incidence of coronary artery aneurysm, dilation of the coronary artery, and in severe cases, myocardial infarction or sudden death. As such, early identification and diagnosis of IKD have become a hot spot in pediatric clinical research. IKD has different characteristics compared with CKD. This article reviews the clinical characteristics and pathogenesis of IKD to help clinicians understand the symptoms of IKD.

**Features of IKD**

**Long duration of fever**

Nie et al. analyzed the clinical symptoms of IKD and found that children with IKD tend to have a longer duration of fever before diagnosis than those with CKD. Tang et al. conducted a clinical analysis of 173 IKD cases and found that the duration of fever in children with IKD was 2 to 21 days, with a median of 7 days. They also found that the duration of fever in children with CKD was 2 to 21 days, with a median of 6 days, which is similar to Takahashi et al.’s results. There was a significant difference between these two populations. Wang et al. analyzed 1004 children with KD in Beijing Children’s Hospital and found that the mean duration of fever in the IKD group (10.3 ± 5.7 days) was significantly longer than that in the KD group (7.4 ± 3.6 days). Therefore, these authors suggested that a differential diagnosis of IKD should be considered if a child has a long duration of fever and the treatment effect is not ideal. A long duration of fever could be attributed to the incomplete clinical symptoms of IKD, which may take some time to confirm. Moreover, some patients with IKD are not responsive to treatment, which leads to a prolonged duration of fever.

**Frequent Bacille Calmette–Guérin scar reaction**

Redness and swelling of Bacille Calmette–Guérin (BCG) scars are prominent features of KD, especially IKD. Nie et al. found that the incidence of BCG scar redness and swelling in the IKD group was significantly higher than that in the CKD group.
By contrast, the incidence of chapped lips, molting of the fingers (or toes), perianal desquamation, skin rash, and swollen cervical lymph nodes was significantly lower in IKD than in CKD. This finding suggests that redness and swelling of BCG scars are more common in children with IKD than in those with CKD. A multicenter clinical study in Mexico reported that redness and swelling of BCG scars have important implications in the acute stage of KD in children aged younger than 5 years. Novais et al. reported that the BCG scar reaction in children aged younger than 6 months is a specific indicator for a diagnosis of IKD. Therefore, long-term fever combined with redness and swelling of BCG scars is an important indicator of IKD.

Young age of onset

Gao et al. showed that the incidence of IKD in infancy was fairly high and the age of onset was relatively low. A study in Italy of 32 children aged younger than 1 year with KD found that 22 (68.7%) had IKD. This result is consistent with the conclusions obtained from an analysis of clinical data of 300 infants with KD in Shengjing Hospital of China Medical University. A transnational multicenter study in Latin America showed that the majority (78.1%) of infants and children aged 6 months or older were initially diagnosed with KD or IKD, while only 38.2% of infants aged younger than 6 months were diagnosed with KD. Nearly all cases of KD in infants aged younger than 3 months have incomplete clinical features. Xiong et al. reported a 26-day-old neonate with KD who showed dilation of the coronary artery and Du described the case of a 24-day-old neonate with IKD complicated by aseptic meningitis. Therefore, the correct diagnosis of KD is important for the health or prognosis of young children.

High incidence of coronary artery lesions

The clinical manifestations of IKD are often incomplete, and clinical diagnosis and treatment are easily delayed. The risk of coronary artery lesions (CAL) is greater in IKD than in CKD. In Japan, the incidence of CAL in children with IKD is 15.0% to 25.0%. A study conducted by the Wenzhou Medical University-affiliated Yuying Children’s Hospital showed that the incidence of CAL in children with IKD was higher than that in children with CKD (33.9% vs. 23.0%), which was also found after gamma globulin therapy (27.5% vs. 14.8%). You et al. showed that infants aged younger than 6 months had a higher incidence of incomplete KD (30%) and cardiac complications (12%) than older children (23% and 2.9%, respectively). The most serious cardiac complication that these authors observed was a coronary artery aneurysm, which may have been caused by severe dilation of the coronary artery. Zhang et al. analyzed 1514 children with KD who were diagnosed at the Children’s Hospital Affiliated with Chongqing Medical University. They found that the incidence of CAL in all children with KD was 51.9%; the incidence rates of CAL in the CKD and IKD groups were 57.2% and 37.9%, respectively. Additionally, the incidence of massive coronary artery aneurysms and thrombosis was significantly higher in the IKD group than in the CKD group. In Italy, 59% of the children with IKD aged younger than 1 year had cardiac involvement. These findings indicate that age is an important risk factor for CAL in patients with KD. A younger age and incompleteness of KD may be independent risk factors for CAL. Incomplete cases are usually younger and have more coronary aneurysms than complete cases, especially among infants aged younger than 1 year.
Enhanced immune tolerance to immunoglobulin

KD is a systemic febrile, inflammatory, vascular disease that commonly causes CAL. Initial treatment of intravenous immunoglobulin (IVIG) can reduce the incidence of CAL. However, some children with KD show complete nonresponse or only a partial response to IVIG. These children may have immune tolerance to this treatment. Downie et al. believed that complete nonresponders are more likely to develop coronary artery aneurysms than partial nonresponders. At present, the reason why this immune tolerance occurs is unclear. Abe et al. found that variable gene expression profiles were correlated with the responses of patients with KD to IVIG administration. Polycythemia rubra vera-1 and granulocyte colony-stimulating factor levels may be good biomarkers for predicting the response to IVIG in patients with KD. Lee et al. provided the first evidence supporting an association between TARC/CCL17 polymorphisms, susceptibility of KD, and IVIG responses in KD. Genetic susceptibility might be an important cause of immune tolerance in IVIG. Dionne et al. considered that KD combined with infection may promote immune tolerance to IVIG, but further research on this possibility is necessary.

In addition to being younger in age and having incomplete symptoms, children with IKD are more prone to immune tolerance to IVIG or a delayed immune response than those with the complete form of disease. This characteristic is also a factor affecting the long duration of fever in children and the risk of coronary artery and heart involvement. Li et al. analyzed the clinical data of 121 patients with KD who were hospitalized in the Pediatric Department of the China–Japan Friendship Hospital. These authors found that the incidence of CAL and nonresponsiveness to IVIG in patients with IKD was significantly higher than that in patients with CKD. In their study, the incidence of nonresponsiveness to IVIG in the CKD group was 8.9%, whereas that in the IKD group was 32.3%. Wu et al. found that serum interleukin-6 levels were significantly elevated in patients with incomplete KD compared with their complete counterparts. Additionally, serum interleukin-6 levels were significantly elevated in patients with IVIG-nonresponsive KD compared with their IVIG-responsive counterparts. These findings suggest that IKD is more resistant to IVIG than CKD. IVIG-resistant KD is a main risk factor for coronary artery involvement in children.

Indicators for diagnosis of IKD

KD should be suspected if a child has a fever that lasts for longer than 5 days, especially if the body temperature exceeds 38.5°C or remains as high as 39°C to 40°C, even after anti-infective treatment. IKD should also be considered if any of the following clinical symptoms of KD occur simultaneously: (1) acute hard edema of the hands and feet, and subsequent finger (toe) molting and perianal desquamation; (2) multiform erythema; (3) nonpurulent conjunctival hyperemia; (4) changes to the lip and oral mucous membranes, such as erythema, fissuring, strawberry tongue, or oral mucosa hyperemia; and (5) nonpurulent cervical lymphadenopathy, which is usually unilateral with at least one lymph node >1.5 cm in diameter. Echocardiography of the heart and great blood vessels should be performed in a timely manner, and various hematological examinations should be conducted to confirm the diagnosis. If an imaging examination shows coronary artery disease or other large-vessel disease and other diseases are excluded, the diagnosis should be IKD. A Scientific Statement for Health
Professionals From the American Heart Association included several related laboratory indicators for a diagnosis of IKD, such as an increased white blood cell count, increased C-reactive protein levels, increased erythrocyte sedimentation rate, increased platelets, increased alanine amionotransferase levels, hypoalbuminemia, asptic pyuria, and cerebrospinal fluid mononucleosis. KD or IKD usually causes the acute phase of the erythrocyte sedimentation rate to significantly increase. When the erythrocyte sedimentation rate is >40 mm/hour, diagnosis of KD can be made, and its sensitivity can exceed 90%. Besides incomplete manifestation of classic symptoms of IKD, IKD may be combined with other complications, including those related to the digestive system (e.g., abdominal pain, diarrhea and vomiting, pancreatitis, cholecystitis), the respiratory system (e.g., cough, runny nose, pulmonary infiltrates), the nervous system (e.g., convulsion, disturbance of consciousness, extreme irritability, asptic meningitis, facial nerve palsy, sensorineural hearing loss), arthritis, arthralgia, urethritis, hydrocele, skin desquamation, phlegmon, and anterior uveitis, among others.

Manlongat and Allen reported a case of a 2-year-old boy with persistent fever and claudication manifesting as bilateral hip synovitis that remained unresolved after repeated antibiotic treatment. A cardiology review and echocardiogram showed dilated and ectatic left coronary arteries involving the left main stem coronary artery, left anterior descending artery, and circumflex artery. The final diagnosis of their case was IKD. Agha and Hamza reported two similar cases, one of a 4-year-old girl and another of a 3-year-old boy. The girl presented with a fever lasting for 1 month that was misdiagnosed as chicken pox, and she also had nonpurulent conjunctivitis and periungual desquamation. The boy presented with a high-grade fever lasting for 7 days and jaundice. In his case, dark urine manifested 2 days after the onset of fever and resolved after 3 days. Laboratory findings and echocardiography confirmed that these two cases were IKD. Goyal and Shah reported an interesting case of IKD with unusual pustulovesicular skin lesions. This case involved a 12-year-old girl with a history of fever and abdominal pain for 10 days and swelling all over her body for 4 days. Swelling initially developed over her left leg and arm, followed by the right extremities, and eventually, the entire body. She had pustulovesicular lesions all over the right forearm and right knee joint, along with an erythematous skin rash over her buttocks and back. Her laboratory test results were consistent with a diagnosis of KD.

Conclusion

Because manifestations of KD commonly occur in other illnesses, such as infection or rheumatic immune disease, KD may be difficult to diagnose, especially in children who present with the incomplete form of this disease. Therefore, the diagnosis of IKD is challenging. Any child presenting with unexplained fever must be carefully monitored and clinicians must be highly vigilant about the possibility of KD.

In summary, early identification of IKD is important for preventing complications from this disease. Obtaining the detailed medical history of a patient and performing a careful physical examination are imperative for detecting the clinical manifestations of KD as soon as possible. Knowledge of potential issues will help health practitioners recommend relevant and appropriate laboratory examinations, and perform a heart and large blood vessel color Doppler ultrasound examination in a timely manner. This strategy can help promote early identification, correct diagnosis, and timely treatment of IKD.
Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iDs
Tianhua Li https://orcid.org/0000-0002-4789-7383
Tingting Liu https://orcid.org/0000-0002-1258-407X

References
1. Kawasaki T. Acute febril mucocutaneous syndrome with lymphoid involvement with specific sesquamation of fingers and toes in children [Article in Japanese] Arerugi 1967; 16: 178–222.
2. McCrindle BW, Rowlwy AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017; 135: 927–999.
3. Rigante D. Kawasaki Disease as the Immune-Mediated Echo of a Viral Infection. Mediterr J Hematol Infect Dis 2020; 12: e2020039.
4. Sudo D, Monobe Y, Yashiro M, et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur J Pediatr 2012; 171: 651–656.
5. Zhao WS, Lu JQ and Yang Y. Comparative analysis of incomplete Kawasaki disease and typical Kawasaki disease. Chongqing Medicine 2012; 41: 3109–3111.
6. Nie Y, Xu HF, Chen CJ, et al. Clinical analysis of children with incomplete Kawasaki disease. Chinese General Practice 2019; 22: 2970–2974.
7. Shivalingam G, Prashanth GP, Hebbal K, et al. Clinical Presentation and Cardiovascular Outcome in Complete versus Incomplete Kawasaki Disease. Indian Pediatr 2017; 54: 844–847.
8. Mastrangelo G, Cimaz R, Calabri GB, et al. Kawasaki disease in infants less than one year of age: an Italian cohort from a single center. BMC Pediatr 2019; 19: 505–520.
9. Lo MS and Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis 2018; 21: 64–69.
10. Xie LP, Yan WL, Huang M, et al. Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017. J Epidemiol 2020; 30: 429–435.
11. Makino N, Nakamura Y, Yashiro M, et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int 2019; 61: 397–403.
12. Kim GB, Park S, Eun LY, et al. Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. Pediatr Infect Dis J 2017; 36: 482–485.
13. Masi L, Franceschelli F, Leocnini G, et al. Can fibroblast growth factor(FGF)-23 circulating levels suggest coronary artery abnormalities in children with kawasaki disease? Clin Exp Rheumatol 2013; 31: 149–153.
14. Song G, Ren W, Liu Z, et al. Incomplete Kawasaki disease with coronary artery aneurysm and coronary sinus thrombus. Pediatr Cardiol 2015; 36: 1097–1099.
15. Tang YJ, Liu T, Yan WH, et al. Clinical analysis of 173 Cases of children with incomplete Kawasaki disease. Chinese Journal of Clinicians (Electronic Edition) 2015; 18: 3461–3464.
16. Takahashi T, Sakakibara H, Morikawa Y, et al. Development of coronary artery lesions in indolent Kawasaki disease following initial spontaneous defervescence: a retrospective cohort study. Pediatr Rheumatol Online J 2015; 13: 1344–1352.
17. Wang LJ, Du ZD, Fu PP, et al. Clinical features of incomplete Kawasaki disease misdiagnosed as lymphadenitis in the first diagnosis. Chin J Appl Clin Pediatr 2015; 30: 1035–1036.
18. Garrido-Garcia LM, Castillo-Moguea A, Vazquez-Rivera M, et al. Reaction of the BCG scar in the acute phase of Kawasaki disease in Mexican children. Pediatr Infect Dis J 2017; 36: e237–e241.
19. Novais C, Fortuanto F, Bicho A, et al. Bacillus Calmette-Guérin reactivation as a sign of incomplete Kawasaki disease. BMJ Case Rep 2016; 43: 3871–3875.

20. Gao Y, Wei L, Han W, et al. A clinical study on 28 cases of early diagnosis of incomplete Kawasaki disease in children. Shaanxi Medical Journal 2015; 44: 1401–1402.

21. Wang C and Yu XY. Clinical features of infant Kawasaki disease and analysis of risk factors for coronary artery injury. China Pediatric Emergency Medicine 2019; 11: 836–839.

22. Elizabeth M, Garcia SD, Emelia B, et al. Presentation and Outcomes of Kawasaki Disease in Latin American Infants Younger Than 6 Months of Age: A Multinational Multicenter Study of the REKAMLATINA Network. Front Pediatr 2020; 16: 384.

23. Li W, Zhang L, Huang P, et al. Clinical features and mid-term follow-up in infants younger than 3 months with Kawasaki disease in a Chinese population. J Paediatr Child Health 2019; 55: 523–527.

24. Xiong P, Liu TL, Chen Y, et al. One case report of incomplete Kawasaki disease of newborn and literature review. Journal of Clinical Pediatrics 2017; 3: 176–178.

25. Du ZQ. A case of neonatal incomplete Kawasaki disease complicated by aseptic meningitis. Chinese Journal of Pediatrics 2014; 52: 63–64.

26. Shi HY, Qiu HX, Jin ZY, et al. Coronary artery lesion risk and mediating mechanism in children with complete and incomplete Kawasaki disease. J Investig Med 2019; 67: 950–956.

27. You MY, Hye WY and Sung HK. Clinical characteristics of Kawasaki disease in infants younger than six months: a single-center study. Korean Circ J 2016; 46: 550–555.

28. Zhang DF, Zhong JR, Wang D, et al. A comparative study of coronary artery lesions in complete Kawasaki disease and incomplete Kawasaki disease. J Clin Pediatr 2018; 36: 14–18.

29. Jakob A, Whelan J and Kordecki M. Kawasaki Disease in Germany: A Prospective, Population-based Study Adjusted for Underreporting. Pediatr Infect Dis J 2016; 35: 129–134.

30. Rigante D, Valentini P, Rizzo D, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int 2010; 30: 841–846.

31. Zheng X, Wu WC, Zhang Y, et al. Changes in and significance of platelet function and parameters in Kawasaki disease. Sci Rep 2019; 9: 17641.

32. Downie ML, Manlhiot C, Latino GA et al. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease. J Pediatr 2016; 179: 124–130.

33. Abe J, Ebata R, Jibiki T, et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol 2008; 122: 1008–1013.e8.

34. Lee CP, Huang YH, Hsu YW, et al. TARC/CCL17 gene polymorphisms and expression associated with susceptibility and coronary artery aneurysm formation in Kawasaki disease. Pediatr Res 2013; 74: 545–551.

35. Dionne A, Le CK, Poupart S, et al. Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection. PLoS One 2018; 13: e0206001.

36. Hwa JC, Woo YK, Sung MP, et al. The Risk Prediction of Coronary Artery Lesions through the Novel Hematological Z-Values in 4 Chronological Age Subgroups of Kawasaki Disease. Medicina (Kaunas) 2020; 56: E466.

37. Li P, Hu JW and Zhou ZS. Comparison of clinical features between incomplete Kawasaki disease and typical Kawasaki disease. Chin J Diffic and Compl Cas 2015; 14: 732–736.

38. Wu Y, Liu FF and Xu Y. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm. Clin Exp Med 2019; 19: 173–181.

39. Türkuçuçar S, Yıldız K, Acar C, et al. Risk factors of intravenous immunoglobulin resistance and coronary arterial lesions in Turkish children with Kawasaki disease. Turk J Pediatr 2020; 62: 1–9.
40. Zhang HY. Clinical analysis of incomplete Kawasaki disease in children. *Asia-Pacific Traditional Medicine* 2019; 9: 95–96.

41. Lin Y, Li XH, Shi L, et al. Interpretation of the 2017 edition of “Diagnosis, treatment and long-term management of Kawasaki disease-American Heart Association scientific statement to medical professionals”. *Chinese Journal of Practical Pediatrics* 2017; 32: 641–648.

42. Singh S, Jindal AK and Pilania RK. Diagnosis of Kawasaki Disease. *Int J Rheum Dis* 2018; 21: 36–44.

43. Manlongat EV and Allen WC. Incomplete Kawasaki disease presenting as bilateral hip synovitis. *J Paediatr Child Health* 2017; 53: 912–914.

44. Agha HM and Hamza HS. Incomplete Kawasaki disease in Egypt. *Glob Cardiol Sci Pract* 2017; 2017: e201724.

45. Goyal JP and Shah VB. Pustulovesicular Skin Eruption as Presenting Feature of Incomplete Kawasaki Disease. *Ann Med Health Sci Res* 2016; 6: 392–395.